[go: up one dir, main page]

MX2009003159A - Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico. - Google Patents

Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico.

Info

Publication number
MX2009003159A
MX2009003159A MX2009003159A MX2009003159A MX2009003159A MX 2009003159 A MX2009003159 A MX 2009003159A MX 2009003159 A MX2009003159 A MX 2009003159A MX 2009003159 A MX2009003159 A MX 2009003159A MX 2009003159 A MX2009003159 A MX 2009003159A
Authority
MX
Mexico
Prior art keywords
growth factor
factor receptor
epidermal growth
therapeutic compositions
boosting
Prior art date
Application number
MX2009003159A
Other languages
English (en)
Inventor
Luis Enrique Fernandez Molina
Greta Garrido Hidalgo
Rolando Perez Rodriguez
Belinda Sanchez Ramirez
Audry Fernandez Gomez
Alejandro Lopez Requena
Irene Beausoleil Delgado
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40223744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003159(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of MX2009003159A publication Critical patent/MX2009003159A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención describe composiciones terapéuticas específicas, que aumentan la eficiencia de la terapia con anticuerpos monoclonales (AcMs) contra el receptor del Factor de Crecimiento Epidérmico (EGFR, del ingles "epidermal growth factor receptor") e interferones (INFs) de tipo I (a/ß).
MX2009003159A 2006-09-29 2007-09-27 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico. MX2009003159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
PCT/CU2007/000017 WO2008037225A1 (es) 2006-09-29 2007-09-27 Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico

Publications (1)

Publication Number Publication Date
MX2009003159A true MX2009003159A (es) 2009-04-06

Family

ID=40223744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003159A MX2009003159A (es) 2006-09-29 2007-09-27 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico.

Country Status (19)

Country Link
US (1) US20100047207A1 (es)
EP (1) EP2070547B1 (es)
KR (1) KR101482957B1 (es)
CN (2) CN101678099A (es)
AR (1) AR063011A1 (es)
AU (1) AU2007302429B2 (es)
BR (1) BRPI0717142A2 (es)
CA (1) CA2664795C (es)
CL (1) CL2007002797A1 (es)
CO (1) CO6160338A2 (es)
CR (1) CR10753A (es)
CU (1) CU23612A1 (es)
MA (1) MA30811B1 (es)
MX (1) MX2009003159A (es)
PE (1) PE20080674A1 (es)
TN (1) TN2009000104A1 (es)
TR (1) TR200902344T1 (es)
UY (1) UY30616A1 (es)
WO (1) WO2008037225A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914209A2 (pt) * 2008-06-20 2015-11-03 Centro Inmunologia Molecular inibidor do receptor do fator de crscimento epidérmico, linha celular, composição farmacêutica, usos do inibidor e de um anticorpo e método
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
BR112018001679A2 (en) * 2015-07-27 2018-09-18 Innocimab Pte Ltd method of treating a patient population, composition, monoclonal antibody, method of predicting whether a patient suffering from pancreatic ductal adenocarcinoma will be unresponsive to treatment with an antibody, and method of treating a patient population

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
CA2129533A1 (en) * 1992-02-10 1993-08-19 Douglas Testa Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
SK14632003A3 (sk) * 2001-05-08 2004-03-02 Merck Patent Gmbh Kombinovaná terapia pri použití anti-EGFR protilátok a antihormonálnych činidiel
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

Also Published As

Publication number Publication date
TN2009000104A1 (en) 2010-08-19
KR20090058566A (ko) 2009-06-09
CR10753A (es) 2009-10-15
AU2007302429B2 (en) 2013-10-03
CA2664795C (en) 2014-06-17
CO6160338A2 (es) 2010-05-20
TR200902344T1 (tr) 2009-08-21
AU2007302429A1 (en) 2008-04-03
CA2664795A1 (en) 2008-04-03
MA30811B1 (fr) 2009-10-01
CN102940883A (zh) 2013-02-27
US20100047207A1 (en) 2010-02-25
PE20080674A1 (es) 2008-07-23
WO2008037225A1 (es) 2008-04-03
UY30616A1 (es) 2008-05-02
EP2070547A1 (en) 2009-06-17
BRPI0717142A2 (pt) 2013-10-15
KR101482957B1 (ko) 2015-01-15
CL2007002797A1 (es) 2008-04-18
CN101678099A (zh) 2010-03-24
EP2070547A4 (en) 2011-11-02
CU23612A1 (es) 2010-12-08
EP2070547B1 (en) 2013-04-24
AR063011A1 (es) 2008-12-23

Similar Documents

Publication Publication Date Title
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MY153893A (en) Antibodies against human il17 and uses thereof
GEP20115324B (en) Tweak binding antibodies
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
IL197300A (en) Antibodies and human antibody parts against the alpha polate receptor for radioimmune treatment of ovarian carcinoma and pharmaceutical preparations and medical kits containing them
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
TW200801038A (en) Immunoglobulins
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2009003159A (es) Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico.
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
UA98756C2 (ru) Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38

Legal Events

Date Code Title Description
FG Grant or registration